CD79A and malaria: One example includes GMZ2.6c, a chimeric vaccine candidate incorporating GLURP, MSP-3, and Pfs48/45 antigens, which elicits naturally acquired antibody responses, including IgA in individuals from malaria-endemic areas of Brazil (Baptista et al., 2022).